These preclinical findings provide evidence that EGFR-targeted CAR-T therapy could be a promising strategy for treating HNSCC, offering targeted tumor destruction while minimizing collateral damage to healthy tissue [82]. This evidence concerns the gene EGFR and neoplasm.